NorthStar Medical Radioisotopes to Present Analysis of Ac-225 Quality Control Methods at Upcoming European Association of Nuclear Medicine (EANM) 2025 Annual Meeting

Multiple analytical methods were assessed to identify those yielding accurate quantification of
Ac-225 radioisotope and drug product radiochemical purity

BELOIT, Wis., October 3, 2025 – NorthStar Medical Radioisotopes LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, is pleased to announce that its experimental study to assess the accuracy and precision of actinium-225 (Ac-225) quality control methods will be presented in an e-poster presentation at the upcoming European Association of Nuclear Medicine (EANM) 2025 Annual Meeting taking place October 4-8 in Barcelona, Spain.

In the e-poster presentation, NorthStar will present the experimental results evaluating the relative effectiveness of multiple analytical methods to accurately define the radiochemical purity of Ac-225 drug product. The presentation will include quantification test results for each method measuring Ac-225 progenies francium-221 and bismuth-213 at their 30 minutes and >5-hour secular equilibria — important findings that further the understanding of acceptable analytical methods to support Ac-225 radiopharmaceutical QC release.

e-Poster Presentation details are below:

Session Date and Location: October 6 in Rooms 133+134
Session Number: 1009
Session Title: e-Poster Presentations Session 7 – Radiopharmaceutical Sciences Committee: Radiochemistry and Quality Control
e-Poster Number: EPS-138
e-Poster Title: Quality control of Actinium-225: Francium-221 to be or not to be?
e-Poster Time: 15:08-15:12
Presenter: Diane Abou, PhD, Principal Radiochemist R&D and Assistant Professor, Washington University in St. Louis

Please visit NorthStar at Booth 28 d for more information on this e-Poster Presentation and to learn about the Company’s copper-67 (Cu-67) and actinium-225 (Ac-225) radioisotope products and its Contract Development and Manufacturing Organization (CDMO) service business from our team.

About NorthStar Medical Radioisotopes, LLC (NorthStar)
NorthStar Medical Radioisotopes is a commercial-stage radiopharmaceutical company at the forefront of advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to a molecule, have the ability to detect and treat cancer and other serious diseases. NorthStar’s expanding industry-leading position in the emerging field of radiopharmaceutical therapy is supported by its unique capabilities in the sophisticated production of radioisotopes, proven management team, and state-of-the-art, environmentally preferable technologies. NorthStar produces copper-67 (Cu-67) and is poised to be one of the first commercial-scale producers of non-carrier added actinium-225 (n.c.a. Ac-225). The Company’s Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs. For more information about NorthStar’s comprehensive portfolio and patient-focused services, visit: www.northstarnm.com.

CONTACTS:
For NorthStar Medical Technologies, LLC
Corporate:
Gauri Gupta
Chief of Staff
312-288-5431
[email protected]

Investor Relations:
Alison Hess
Vice President, Finance
608-295-9806
[email protected]